Oncolytics Biotech Inc ONCY

Keytruda resistance shown as a monotherapy in anal cancer

[Noteable]

January 25, 2024 -   In the phase II study, the ORR to pembrolizumab monotherapy was 9.4% and the median progression-free survival was 2.2 months. 

Conclusions Pembrolizumab has durable efficacy in a rare subset of anal cancers. However, despite persistence of HPV infection, indicated by circulating HPV DNA, most advanced anal cancers have low numbers of tumor-associated CD8+PD-1+ T cells and are resistant to pembrolizumab.

https://jitc.bmj.com/content/12/1/e008436?rss=1

This study demonstrates that immune checkpoint inhibitors are relatively ineffective as a monotherapy and require combination with ONCY's oncolytic virus pelareorep to affect a favorable tumor microenvironment (TME) for the addition of checkpoint inhibitors and the enhancement of CD8 + PD-(L)1 + T cells for an effective anti-tumor response.

https://jitc.bmj.com/content/12/1/e008436?rss=1

[Noteable]

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of

[Noteable]

Two different studies in  metastatic or locally advanced incurable anal squamous cell carcinoma. One with pembrolizumab as a monotherapy and one with pelareorep in combination with atezolizumab. The monotherapy pembrolizumab study reported an ORR of 9.4% and a 2.2 month PFS.  The I/O combination pelareorep + atezolizumab study reported an ORR of 35.5% and results that have

[Noteable]

This is all good news ... pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and  is considered a biomarker for future response rate.

[Noteable]

The facts show that ... pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and is considered a biomarker for future response rate. Couldn't be much more factual or  clearer than this.

[13X2413]

Quentin's comments are much clearer and specific to ONC. 

[Azzak34]

So, from his post that you have cited. Reiterate the facts!!! 

[Noteable]

        Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  

[Noteable]

In a Nov. 9, 2023 press release— Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg,

[Noteable]

Merck (MSD) is now looking to combine other I/O agents with Keytruda to enhance the immune checkpoint inhibitors effectiveness. ONCY's pelareorep is demonstrating that it fits Merck's need.

[Noteable]

Another approval for Keytruda further opens the door for ONCY's pelareorep in combination with immune checkpoint inhibitors. June 18, 2024  - Merck & Co.’s Keytruda has received the FDA’s green light for use in combination with chemotherapy, followed by the PD-1 inhibitor as a single agent, in patients with primary advanced or recurrent endometrial cancer, the company said Monday

[Noteable]

This study demonstrates that immune checkpoint inhibitors are relatively ineffective as a monotherapy and require combination with ONCY's oncolytic virus pelareorep to affect a favorable tumor microenvironment (TME) for the addition of checkpoint inhibitors and the enhancement of CD8 + PD-(L)1 + T cells for an effective anti-tumor response.   https://jitc.bmj.com/content/12/1/e008436

[13X2413]

Nice. But why is share price at $1.50?

[Noteable]

Why?? ...those manipulative trader/brokers like you  numbersxnumbers, and the likes of Quentin30, lonc17, O'henry,, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly